David J. Matly, M.B.A., is a seasoned biotechnology executive with over 20 years of experience in the pharmaceutical and life sciences industries. He earned his Master of Business Administration from the Wharton School of the University of Pennsylvania, complemented by a Bachelor of Science in Biology from Duke University. Matly began his career at Merck & Co., where he advanced through roles in business development and strategic planning, contributing to the launch of several blockbuster drugs. He later held executive positions at Genentech and Amgen, spearheading partnerships that secured over $1.5 billion in funding and advanced multiple clinical-stage programs from preclinical to Phase III trials. Throughout his career, Matly has been recognized for his expertise in translating scientific innovation into commercial success. Notable achievements include leading the acquisition of a promising immunology platform at Amgen, which accelerated revenue growth by 25%, and serving on the board of directors for several venture-backed startups. His strategic acumen has earned him awards such as the Biotech Executive of the Year from BioSpace in 2018. Matly's deep understanding of regulatory landscapes and market dynamics has positioned him as a key advisor to industry leaders. As President of InhibRx Biosciences Inc., Matly oversees all aspects of the company's operations, including research and development, clinical programs, and business expansion. Under his leadership since 2020, InhibRx has advanced its proprietary INH platform for targeted protein degradation therapies, securing $150 million in Series C financing and initiating two Phase II trials for inflammatory diseases. Matly continues to drive InhibRx's mission to deliver transformative treatments, fostering collaborations with global pharma giants to bring novel therapies to patients in need.